Radionuclide

Monopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent Developments

Retrieved on: 
Thursday, March 28, 2024
Cancer, Receptor (biochemistry), Radionuclide, Patient, Neoplasm, PET, G&A, Worldwide Angel, Actinium-225, MTIC, Pancreatic cancer, Investment, Fifth, Therapy, Clinical trial, Safety

WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.

Key Points: 
  • WILMETTE, Ill., March 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced fourth quarter and full-year 2023 financial results and summarized recent developments.
  • Results for the Fourth Quarter and Year Ended December 31, 2023, Compared to the Fourth Quarter and Year Ended December 31, 2022
    Cash, cash equivalents and short-term investments as of December 31, 2023, were $7.3 million.
  • R&D expenses for the fourth quarter of 2023 were $1.0 million compared to $2.1 million for the fourth quarter of 2022.
  • G&A expenses for the fourth quarter of 2023 were $0.9 million, compared to $0.8 million for the fourth quarter of 2022.

Molecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023

Retrieved on: 
Thursday, March 14, 2024
CD33, GSK, Patient, Macrophage, Society, CD3, CD47, DLL3, Therapy, Molecular Partners, TME, Partner, DRS, ASH, AML, SNMMI, Partnership, RDT, Radionuclide, Tetra, Novartis, HSCT, MHS, FTE, Exposition, Delta, Safety, SITC, Amgen, Hematopoietic stem cell transplantation, FAP, Disease, Nuclear medicine, Immunotherapy, District court, Neoplasm, EANM, Alpha particle, JNJ, Tumor microenvironment, Gene family, CD70, AACR, CD40, CHF, CD123, NK, Engineering, Antigen, Molecule, Annual general meeting, Toxicity, CD16, B cell, Conference, MBA, DARPin, Data, Molecular imaging, Pharmaceutical industry

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., March 14, 2024 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.

Key Points: 
  • 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced its corporate highlights and audited financial results for the full year 2023.
  • “2023 was a year of successful innovation and execution on our strategy, focusing on novel mechanisms that we believe only DARPin therapies can deliver.
  • In addition to the above updates, Molecular Partners continued to progress its RDT portfolio of projects in partnership with Novartis.
  • In the financial year 2023, Molecular Partners recognized total revenues and other income of CHF 7.0 million (2022: CHF 189.6 million) and incurred total expenses of CHF 68.1 million (2022: CHF 73.0 million).

RLS Radiopharmacies Partners with Eckert & Ziegler to Expand Production of Gallium-68-Based Radiopharmaceuticals

Retrieved on: 
Thursday, April 4, 2024
Oncology, Medical Devices, Health, Radiology, Pharmaceutical, Biotechnology, Gallium, Diagnosis, Radionuclide, Glomus tumor, Prostate cancer, USP, Half-life, Actinium-225, Partnership, Patient, Pharmacy, RLS, PET, Splenic infarction, Cancer, SDAX, Radiopharmaceutical, Investment, Cyclotron, ISO, Positron emission tomography, DSM-IV codes, Gelastic seizure, Medical imaging

Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.

Key Points: 
  • Under the partnership, all 31 of RLS’s radiopharmacies will be equipped with Eckert & Ziegler’s advanced GalliaPharm® generators, which the radiopharmacy network will utilize to produce high-quality, life-enhancing Gallium-68-based (Ga-68) radiopharmaceuticals.
  • “A powerful diagnostic isotope, Gallium has an extremely short half-life, necessitating the need for Ga-68-based radiopharmaceuticals to be produced within minutes of patient dosing.
  • This signifies a major leap forward in our commitment to advancing healthcare and improving patient outcomes through cutting-edge radiopharmaceuticals."
  • To date, RLS has installed Eckert & Ziegler’s GalliaPharm® generators within most of its locations and anticipates the remaining radiopharmacies will be operational by the end of June.

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Ariceum Therapeutics to present new radioligand therapy data at American Association for Cancer Research (AACR) Annual Meeting 2024

Retrieved on: 
Thursday, April 4, 2024
Diagnosis, Research, RLT, Radionuclide, UCB, Tissue, Messenger, Abstract (summary), AACR, Therapy, Macrocycle, Poster, Annual general meeting, Peptide, Pharmaceutical industry

The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.

Key Points: 
  • The findings describe the selection and initial characterization of macrocyclic peptides against an undisclosed target discovered using UCB's mRNA-display technology platform, ExtremeDiversity™.
  • Macrocyclic peptides are potent ligands for radioligand therapeutics (RLT) that aim to selectively deliver radioisotopes to cancer tissues to eradicate tumor cells while limiting the damage to surrounding tissues.
  • These data have positive implications for the future development of RLT and are a potential game-changer in precision cancer therapy.
  • AACR's Annual Meeting is the perfect industry forum at the forefront of cancer research at which to present our findings."

Nusano Opens Radiochemistry Laboratory to Advance Isotope Commercialization and Customer Collaboration

Retrieved on: 
Monday, March 11, 2024
Actinium-225, Biotechnology, Drug development, Growth, Foot, Radionuclide, Risk, Radiochemistry, Physics, Health, Patient, Cancer

“Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.

Key Points: 
  • “Nusano is less than 12 months away from bringing critical, new radioisotope supplies to researchers, drugmakers and patients.
  • We expect to begin producing non-carrier added lutetium-177 in Q1 2025, followed by actinium-225 in the second half of the year,” said Chris Lowe, CEO of Nusano.
  • Nusano is working to supply the fight against cancer by combining the company’s expertise in physics and radiochemistry to meet the medical isotope needs of today and enable the cancer radiotherapeutics of tomorrow.
  • Anna Goldberg, director of Radiochemistry and Production Operations for Nusano, added, “Nusano’s radiochemistry team is a world-class group of experts working at the forefront of their field.

Monopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma Program

Retrieved on: 
Tuesday, March 5, 2024
Neoplasm, Actinium-225, SPECT, MD, Radionuclide, Therapy, Receptor (biochemistry), Patient, Radiopharmaceutical, Pancreatic cancer, Cancer, Medical imaging

This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.

Key Points: 
  • This is an extension of the tumor imaging and efficacy data Monopar released on February 22 ( link ), where Monopar disclosed biodistribution data with a diagnostic imaging radioisotope (Zirconium-89) as well as efficacy data with therapeutic radioisotopes (e.g., Actinium-225) bound to MNPR-101 in human tumor xenograft models.
  • Two of the most commercially successful radiopharmaceuticals, Pluvicto® and Lutathera™, use the therapeutic radioisotope Lutetium-177 (Lu-177).
  • Monopar collected a sequential SPECT imaging time-series utilizing MNPR-101 conjugated to Lu-177 (MNPR-101-Lu) in a uPAR-expressing human pancreatic cancer xenograft model.
  • “These data further support the potential of a MNPR-101 based radiopharmaceutical to provide a very meaningful clinical benefit to patients with uPAR-positive tumors.”

Monopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced Cancers

Retrieved on: 
Thursday, February 22, 2024
Neoplasm, Actinium-225, Cancer, Radionuclide, Therapy, Receptor (biochemistry), Patient, Clinical trial, Pancreatic cancer, PET

This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.

Key Points: 
  • This novel first-in-class radiopharma program targets cancers expressing the urokinase plasminogen activator receptor (uPAR), which include a majority of all triple-negative breast, colorectal, and pancreatic cancers.
  • Figure 1 below shows the before and after optimization of MNPR-101-Zr, Monopar’s radiopharmaceutical imaging agent for advanced solid tumors expressing uPAR.
  • Preclinical data to date demonstrate compelling and durable anti-tumor benefits with MNPR-101 conjugated to therapeutic radioisotopes.
  • “We are aiming to present these promising preclinical results at an upcoming scientific meeting.”

EQS-News: Eckert & Ziegler to Supply Nucleus Radiopharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Monday, February 5, 2024
Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Berlin, Germany and Rochester, MN, USA – January 31, 2024 – Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus Radiopharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.

Eckert & Ziegler to Supply Nucleus RadioPharma with Therapeutic Radioisotopes Ac-225 and Lu-177

Retrieved on: 
Wednesday, January 31, 2024
Research, Genetics, Health Technology, Biotechnology, Radiology, General Health, Pharmaceutical, Health, Science, Oncology, Radionuclide, SDAX, Actinium-225, GMP, Radiopharmaceutical, Medical imaging

Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.

Key Points: 
  • Eckert & Ziegler (ISIN DE0005659700, SDAX) and Nucleus RadioPharma (Nucleus) signed extensive supply agreements for major therapeutic radioisotopes.
  • Eckert & Ziegler will serve as core supplier for high-quality Lutetium-177 (Lu-177) as well as Actinium-225 (Ac-225), both in non-carrier-added form.
  • Nucleus will use the radioisotopes to complement and advance their services for clinical development and manufacturing of radiopharmaceuticals.
  • "We are pleased to support Nucleus’ activities with our Actinium-225 and Lutetium-177 supply, and thus contribute to the advancement of radiotherapies,” stated Dr. Harald Hasselmann, CEO of Eckert & Ziegler.